Good MorningThe uptrend in equities was confirmed on Friday when the broad market advanced roughly 1% to set a new all-time high. The move was driven by better-than-expected revenue and earnings as well as upwardly revised guidance from a large number of companies reporting during the week. The key takeaway is that economic conditions remain strong despite mounting concerns for inflation. While most S&P comp companies are navigating the inflationary environment successfully there are a few who aren't.
The risks for the market this week are twofold. On one hand, about 20% of the S&P 500 Index is scheduled to report earnings while on the other, we're waiting for the next policy decision from the FOMC. Along with that is a key read on inflation due on Friday that could spook the market. The PCE price index has risen hotter than expected for three months and is accelerating, another month of similar results further cloud the outlook.
Featured: The Tobacco Industry Change is Here! (TAAT MGMT) 
|
Markets | | | After this week’s incredible recovery in the market that obliterated any bears who were caught offsides, there are several stocks breaking out to new highs that could be worth a look at this time. Breakouts are always a great way to gauge the overall level of bullishness in the market, which i... Read the Full Story |
|
From Our PartnersI call it my "Dividend Map", and I'll show you exactly where to find the safest companies that pay the highest yields. (HINT: Texas has 6 of these companies sending huge payouts that average 69%!). I'm willing to send you my Map... but only if you click here right now. If I don't have your name on my list in the next 2 hours, I'll assume you don't want to make monster dividends. | | Click here right now.
|
|
Markets | | | TThe S&P 500 (ASX: SPY) has been making new highs it seems almost every week with a performance of over 16% year-to-date (YTD) in 2021. The question on investor’s minds is how long this strong uptrend can go and where it will go Read the Full Story |
|
Tech | | | World shares were mostly lower on Monday after stocks rallied to records on Wall Street, with the Dow Jones Industrial Average closing above the 35,000 level Friday for the first time.
Britain's FTSE 100 lost 0.4% to 6,998.08 and Germany's DAX declined 0.7% to 15,567.11. In Paris, th... Read the Full Story |
|
From Our PartnersElon Musk and Tesla still have one BIG PROBLEM that could derail the whole electric vehicle market. No, it’s not lithium. It’s another resource that’s even more critical for electric vehicles. And right now there’s one tiny $4 stock that is uniquely set up to benefit from this booming demand. | | | | Click here to see why |
|
Tech | | | Shares were mostly lower in Asia on Monday, where Tokyo advanced while markets in Hong Kong and Shanghai fell sharply.
Fresh news of regulatory moves against Chinese IT and education industry companies pulled shares lower in Hong Kong and Shanghai.
In Japan, preliminar... Read the Full Story |
|
Markets | | | Asian shares were mixed on Monday after stocks rallied to records on Wall Street, with the Dow Jones Industrial Average closing above the 35,000 level for the first time.
Tokyo advanced after a 4-day weekend as the Olympic Games began, a year late. Benchmarks fell in Hong Kong and Sh... Read the Full Story |
|
From Our PartnersThis company is about to flip big tobacco on its head with a game-changing new roll out! | | | | Continue Reading |
|
Politics | | | CANBERRA, Australia — AstraZeneca has backed the advice of Australia’s immunization expert body that Sydney residents should take any COVID-19 vaccine they can get.
The Australian Technical Advisory Group on Immunisation, known as ATAGI, recommended on July 13 that adults under the ag... Read the Full Story |
|
Markets | | | Entertainment and toy products maker JAKKS Pacific (NASDAQ: JAKK) stock is awakening and recovering as it surges through pre-COVID price levels. The licensor of popular brands like Sonic the Hedgehog, Super Mario Brothers, Apex Legends, Disney (NYSE: DIS) Frozen, Mulan, Princess, and Raya IPs is exp... Read the Full Story |
|
Markets | | | As coronavirus cases ravaged India this spring, Anil Sharma visited his 24-year-old son Saurav at a private hospital in northwest New Delhi every day for more than two months. In May, as India's new COVID-19 cases broke global records to reach 400,000 a day, Saurav was put on a ventilator.
... Read the Full Story |
|
Markets | | | American Express (NYSE: AXP) Amex was among stocks helping to propel the Dow higher Friday, following a better-than-expected earnings report.
American Express, which comprises 3.23% of the price-weighted index, provides a good illustration of the rebound in business and consumer spending afte... Read the Full Story |
|
Markets | | |
Should you blindly sign up for your company's 401(k) plan? No way! Not without some serious consideration, anyway.
It's easy to assume that your employer has your best interests at heart and will "take care of you." However, that's not always the case.
Let's take a look at three signs you'... Read the Full Story |
|
The Early Bird Stock Of The Day Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California. | | View Today's Stock Pick |
|
